Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

Shankar P. Singh, Ravi; S. Toussi, Sima; Hackman, Frances; L. Chan, Phylinda; Rao, Rohit; Allen, Richard; Van Eyck, Lien; Pawlak, Sylvester; P. Kadar, Eugene; Clark, Frances; Shi, Haihong; S. Anderson, Annaliesa; Binks, Michael; Menon, Sandeep; Nucci, Gianluca; Bergman, Arthur

doi:10.1002/cpt.2603

Public

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

Shared by NobleBlocks on May 4, 2022 • 12:00 AM UTC

Authors:

Ravi Shankar P. Singh

Sima S. Toussi

Frances Hackman

Abstract

Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF‐07321332), the first orally bioavailable, severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) M pro inhibitor against th...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!